Roche präsentiert neue Studiendaten zu Fenebrutinib bei progressiver Multipler Sklerose

Reuters02-08 04:40

Roche präsentiert neue Studiendaten zu Fenebrutinib bei progressiver Multipler Sklerose

Roche Holding AG hat neue Daten aus der Phase-III-Studie FENtrepid zu dem Prüfpräparat Fenebrutinib bei primär progredienter Multipler Sklerose (PPMS) bekannt gegeben. Die Ergebnisse wurden als Spätmeldung auf dem ACTRIMS Forum 2026 in San Diego präsentiert. Fenebrutinib erreichte in der Studie den primären Endpunkt der Nicht-Unterlegenheit gegenüber OCREVUS (Ocrelizumab) in Bezug auf die Reduktion des Fortschreitens der Behinderung. Zudem wurde eine numerische Reduktion des Risikos der Behinderungsprogression um 12 % im Vergleich zu OCREVUS beobachtet. Eine regulatorische Einreichung von Fenebrutinib bei PPMS und schubförmig-remittierender MS ist nach Abschluss der laufenden Phase-III-Studie FENhance 1 im ersten Halbjahr 2026 geplant.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Roche Holding AG published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW1001163481-en) on February 07, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2609752967?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-08 04:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2609752967","market":"fut","top_or_hot":-1,"title":"Roche präsentiert neue Studiendaten zu Fenebrutinib bei progressiver Multipler Sklerose","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Roche präsentiert neue Studiendaten zu Fenebrutinib bei progressiver Multipler Sklerose\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Roche Holding AG hat neue Daten aus der Phase-III-Studie FENtrepid zu dem Prüfpräparat Fenebrutinib bei primär progredienter Multipler Sklerose (PPMS) bekannt gegeben. Die Ergebnisse wurden als Spätmeldung auf dem ACTRIMS Forum 2026 in San Diego präsentiert. Fenebrutinib erreichte in der Studie den primären Endpunkt der Nicht-Unterlegenheit gegenüber OCREVUS (Ocrelizumab) in Bezug auf die Reduktion des Fortschreitens der Behinderung. Zudem wurde eine numerische Reduktion des Risikos der Behinderungsprogression um 12 % im Vergleich zu OCREVUS beobachtet. Eine regulatorische Einreichung von Fenebrutinib bei PPMS und schubförmig-remittierender MS ist nach Abschluss der laufenden Phase-III-Studie FENhance 1 im ersten Halbjahr 2026 geplant.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Roche Holding AG published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW1001163481-en) on February 07, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Roche präsentiert neue Studiendaten zu Fenebrutinib bei progressiver Multipler Sklerose</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRoche präsentiert neue Studiendaten zu Fenebrutinib bei progressiver Multipler Sklerose\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-08 04:40</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Roche präsentiert neue Studiendaten zu Fenebrutinib bei progressiver Multipler Sklerose\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Roche Holding AG hat neue Daten aus der Phase-III-Studie FENtrepid zu dem Prüfpräparat Fenebrutinib bei primär progredienter Multipler Sklerose (PPMS) bekannt gegeben. Die Ergebnisse wurden als Spätmeldung auf dem ACTRIMS Forum 2026 in San Diego präsentiert. Fenebrutinib erreichte in der Studie den primären Endpunkt der Nicht-Unterlegenheit gegenüber OCREVUS (Ocrelizumab) in Bezug auf die Reduktion des Fortschreitens der Behinderung. Zudem wurde eine numerische Reduktion des Risikos der Behinderungsprogression um 12 % im Vergleich zu OCREVUS beobachtet. Eine regulatorische Einreichung von Fenebrutinib bei PPMS und schubförmig-remittierender MS ist nach Abschluss der laufenden Phase-III-Studie FENhance 1 im ersten Halbjahr 2026 geplant.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Roche Holding AG published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW1001163481-en) on February 07, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NDAQ","symbol_name":"纳斯达克OMX交易所","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260207:nNDL7v5VJW:1","article_id":"2609752967","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2609752967","pubTimestamp":1770496822,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Roche Holding AG published the original content used to generate this news brief via GlobeNewswire  on February 07, 2026, and is solely responsible for the information contained therein.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NDAQ":"纳斯达克OMX交易所","SG9999014013.SGD":"United Global Durable Equities Fund Dis SGD","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","BK4588":"碎股","BK4585":"ETF&股票定投概念","BK4112":"金融交易所和数据","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","SG9999014005.SGD":"United Global Durable Equities Fund Acc SGD","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","SG9999014039.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) INC","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","SG9999014021.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) ACC"},"translate_title":"罗氏公布Fenebrutinib治疗进行性多发性硬化症的新研究数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDAQ":0.9},"content_text":"Roche präsentiert neue Studiendaten zu Fenebrutinib bei progressiver Multipler Sklerose\n    \n\n        Roche Holding AG hat neue Daten aus der Phase-III-Studie FENtrepid zu dem Prüfpräparat Fenebrutinib bei primär progredienter Multipler Sklerose (PPMS) bekannt gegeben. Die Ergebnisse wurden als Spätmeldung auf dem ACTRIMS Forum 2026 in San Diego präsentiert. Fenebrutinib erreichte in der Studie den primären Endpunkt der Nicht-Unterlegenheit gegenüber OCREVUS (Ocrelizumab) in Bezug auf die Reduktion des Fortschreitens der Behinderung. Zudem wurde eine numerische Reduktion des Risikos der Behinderungsprogression um 12 % im Vergleich zu OCREVUS beobachtet. Eine regulatorische Einreichung von Fenebrutinib bei PPMS und schubförmig-remittierender MS ist nach Abschluss der laufenden Phase-III-Studie FENhance 1 im ersten Halbjahr 2026 geplant.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Roche Holding AG published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW1001163481-en) on February 07, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2609752967","isCrawlerRequest":true}